The composition of cell-based therapies obtained from point-of-care devices/systems which mechanically dissociate lipoaspirate: a scoping review of the literature

Perry Liu1*, Binay Gurung1, Irrum Afzal1, Matteo Santin2, David H. Sochart1, Richard E. Field1,3, Deiary F. Kader1 and Vipin Asopa1

Abstract

Purpose: Cell-based therapies using lipoaspirate are gaining popularity in orthopaedics due to their hypothesised regenerative potential. Several ‘point-of-care’ lipoaspirate-processing devices/systems have become available to isolate cells for therapeutic use, with published evidence reporting their clinical relevance. However, few studies have analysed the composition of their ‘minimally-manipulated’ cellular products in parallel, information that is vital to understand the mechanisms by which these therapies may be efficacious. This scoping review aimed to identify devices/systems using mechanical-only processing of lipoaspirate, the constituents of their cell-based therapies and where available, clinical outcomes.

Methods: PRISMA extension for scoping reviews guidelines were followed. MEDLINE, Embase and PubMed databases were systematically searched to identify relevant articles until 21st April 2022. Information relating to cellular composition and clinical outcomes for devices/systems was extracted. Further information was also obtained by individually searching the devices/systems in the PubMed database, Google search engine and contacting manufacturers.

Results: 2895 studies were screened and a total of 15 articles (11 = Level 5 evidence) fulfilled the inclusion criteria. 13 unique devices/systems were identified from included studies. All the studies reported cell concentration (cell number regardless of phenotype per millilitre of lipoaspirate) for their devices/systems (range 0.005–21 × 10⁶). Ten reported cell viability (the measure of live cells- range 60–98%), 11 performed immuno-phenotypic analysis of the cell-subtypes and four investigated clinical outcomes of their cellular products. Only two studies reported all four of these parameters.

Conclusion: When focussing on cell concentration, cell viability and MSC immuno-phenotypic analysis alone, the most effective manual devices/systems were ones using filtration and cutting/mincing. However, it was unclear whether high performance in these categories would translate to improved clinical outcomes. Due to the lack of standardisation and heterogeneity of the data, it was also not possible to draw any reliable conclusions and determine the role of these devices/systems in clinical practice at present.

Level of Evidence: Level V Therapeutic.
Introduction
The underlying principle of cell-based therapy is the targeted delivery of donor cells to achieve a medicinal benefit [28] and this has been long established in applications like bone marrow transplantation. There is now growing interest in orthopaedics as to whether cell-based therapies can be used to treat diseases such as osteoarthritis (OA), in the hope that they can repair damaged tissue and reduce the need for surgical intervention [43]. Mesenchymal stem cells (MSCs) are found in many locations around the body such as bone marrow and adipose tissue [23], with those from the latter termed adipose-derived stem cells (ASCs) [79].

Initially, it was believed that MSCs were the mediators of tissue repair because of their pluripotent ability to differentiate into cartilage and bone tissue [32]. However, due to an inability to control for differentiation in vivo, new evidence suggests that MSCs (when isolated) behave as pericytes and exert their regenerative effects through paracrine or immunogenic ways [13], rather than cell differentiation. It has therefore been suggested that the acronym ‘MSC’ be changed to ‘medicinal signalling cells’ accordingly [14].

Small ASC numbers can be isolated in the cellular concoctions of mechanically dissociated and/or enzymatically digested lipoaspirate. Other cell-types present include fibroblasts, immune cells, epithelial cells and endothelial cells [11]. ASCs can be cultured to increase/expand their numbers [70], but this is time-consuming and unsuitable for point-of-care (POC) treatment [70]. Expansion also involves extensive cell manipulation, and it is unclear whether their properties can be preserved between culture and re-injection [5, 30, 53]. Therefore, using freshly processed lipoaspirate (containing heterogeneous cells and not just ASCs) has become more popular [77] (Fig. 1). Although higher cell numbers are generated with enzyme digestion [4], these processes can alter cell architecture [60], so mechanical-only methods have now been favoured for this purpose.

These mechanical methods involve processes like centrifugation, filtration, cutting/mincing, decantation and washing. The inconvenience of needing various equipment at each stage has led to an increasing number of devices or systems that have been developed as ‘all-in-one’ options for easier therapeutic delivery [9]. Although studies have reported clinical benefit from using these devices/systems, little is known about the composition of their cell-based therapies and what is being re-injected into patients [4, 52] - information needed to help us understand how these therapies work. Therefore, the aim of this literature review was to summarise the available mechanical lipoaspirate-processing devices/systems and what they produce. Where available, the composition of their cellular products and clinical outcome data were compared in parallel.

Methods
This study was in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analysis extension for scoping reviews (PRISMA-ScR) guidelines [69] and was registered on the PROSPERO’s international prospective register of systematic reviews.
The five-stage scoping review process described by Arksey and O’Malley [3] was followed and adaptations from the Joanna Briggs Institute [48] were incorporated.

**Stage 1: Identifying the research question**

*A preliminary review of the literature showed that:*

1) There was a paucity of information about these POC devices/systems.
2) Although clinical outcomes had been reported from using their cell-based therapies, it was unclear what was being reinjected into patients.

This led to the following research question being devised “What do these cell-based therapies contain?” (When using POC devices/systems which mechanically dissociate lipoaspirate).

**Stage 2: Identifying the relevant studies**

MEDLINE and Embase databases were searched via the Healthcare Database Advanced Search (HDAS) engine from inception to date 1st September 2021. A supplemental search of the native PubMed database was performed as well. A search syntax was formulated (Supplementary material- AdditionalFile1.docx) which focussed on four domains- cell type, adipose tissue, cell isolation and device/system.

Medical Subject Heading (MeSH)-terms and keywords were used to identify relevant articles. The searches were re-run on 21st April 2022 in the Ovid search engine to capture any additional studies. All efforts were made to search the gray literature for relevant articles missed, including a manual search of the references of the included studies and relevant review articles.

**Stage 3: Study selection**

After deduplication, two reviewers (PL, BG) independently screened the titles and abstracts for relevance. Following this, the full texts of the remaining articles were assessed for eligibility (Table 1). A third senior reviewer (VA) was consulted in the event of a disagreement about a study’s inclusion.

**Outcome Measures (definitions):**

- **Cell concentration**: Number of cells (irrespective of phenotype) per millilitre of processed lipoaspirate.
- **Cell yield**: Overall number of cells (irrespective of phenotype) that are present in the final product.
- **Cell viability**: A measure of the proportion of cells that are live and healthy [1].
- **Cell phenotype**: Hallmark characteristics of a cell and its surface markers.

To provide more information about the devices/systems captured in the included studies, an additional search of each device/system was performed in the PubMed database and Google search engine.

**Stage 4: Charting the data**

Information about study characteristics (Table 2), laboratory analysis (Table 3) and immunophenotyping (Table 4) were extracted and tabulated in a database.

| Inclusion criteria | Exclusion criteria |
|--------------------|--------------------|
| -Published articles in English or with translation freely available (from any period) | -Adipose tissue obtained from animals or cadavers |
| -Full text accessibility | -Enzyme use prior to device/system administration or enzymatic-based devices/systems |
| -Study designs (any of): Randomised control trials (RCTs), non-RCTs, prospective and retrospective cohort studies, cross-sectional studies, case–control studies, case series | -Devices/systems involved in lipotransfer or the harvesting process of adipose tissue eg. AquaVage, and LipiVage [78] |
| | -Case reports, review articles, abstracts, letters and non-peer reviewed articles |
| | -Studies reported in any other language apart from English with no translation |

**Table 1** Inclusion, exclusion and PICO (Population Intervention Comparison and Outcome) criteria for this review

| PICO criteria | Exclusion criteria |
|---------------|--------------------|
| **Population** | Human subjects (any age) including source of adipose tissue |
| **Intervention/Exposure** | Use of commercially available devices and systems to mechanically process lipoaspirate to obtain fresh cells |
| **Control/Comparator** | Any other lipoaspirate-processing technique |
| **Outcome(s)** | Cell concentration at point of isolation, without further expansion in culture |
| **Primary** | Cell viability, phenotypic analysis and clinical application of the cellular product |
| **Secondary** | |
The separate search of each device/system was used to ascertain their individual characteristics and use in clinical applications (Table 5). The manufacturer website for each was also analysed for relevant information and peer-reviewed literature. Where possible, companies were contacted by email for any additional articles.

Stage 5: Collating, summarising, and reporting the results
Due to heterogeneity of the data, a formal meta-analysis could not be performed. A narrative analysis of the POC devices/systems, the composition of their therapies, and clinical outcomes (where available) was conducted.

| Year of Study | Author | Affiliation with company of device/system or other conflict | Study Design | Level of evidence (Therapeutic) | Journals | No. of donors for lipoaspirate | Clinical Outcomes measured? |
|---------------|--------|-----------------------------------------------------------|-------------|---------------------------------|----------|-----------------------------|-----------------------------|
| 2015          | Domenis et al. [24] | None | Prospective Cohort Study | 2 | Stem Cell Research and Therapy | 6 | Yes (Breast reconstruction) |
| 2015          | Gentile et al. [29] | None | Prospective Cohort Study | 2 | Plastic and Reconstructive Surgery | 20 (10 for each device/system) | Yes (Breast reconstruction) |
| 2016          | Cicione et al. [16] | MyStem EVO kits donated by MyStem LCC | Descriptive laboratory study | 5 | Plastic and Reconstructive Surgery | 14 | No |
| 2017          | Dragoo et al. [27] | Adiprep kit donated by Harvest Technologies Corp | Descriptive laboratory study | 5 | The American Journal of Sports Medicine | 7 | No |
| 2017          | Morselli et al. [42] | None | Descriptive laboratory study | 5 | Wound Repair and Regeneration | 18 | No |
| 2017          | Streit et al. [63] | None | Descriptive laboratory study | 5 | Plastic and Reconstructive Surgery | 14 | No |
| 2018          | Tarallo et al. [65] | None | Prospective Cohort Study | 2 | Plastic and Reconstructive Surgery | 20 | Yes (Wound healing) |
| 2018          | Vezzani et al. [73] | Several authors have affiliations with Lipogems | Descriptive laboratory study | 5 | Stem Cells Translational Medicine | - | No |
| 2019          | Cohen et al. [17] | Several authors have affiliations with both Liposcube Ltd and Tulip Medical | Descriptive laboratory study | 5 | Aesthetic Surgery Journal | 10 | No |
| 2019          | Sese et al. [61] | Partially funded by Tulip Medical and kit donated by Tulip Medical | Descriptive laboratory study | 5 | Plastic and Reconstructive Surgery | 6 | No |
| 2019          | Winnier et al. [77] | Several authors hold positions at InGeneron, Inc | Descriptive laboratory study | 5 | Public Library of Science | 12 | No |
| 2020          | Copcu et al. [18] | None | Case Series | 4 | Aesthetic Surgery Journal | 24 | Yes (Fat grafting) |
| 2020          | Dai Pre et al. [20] | None | Descriptive laboratory study | 5 | International Journal of Molecular Sciences | 9 | No |
| 2020          | Tiryaki et al. [66] | Several authors have affiliations with both Liposcube Ltd and Tulip Medical | Descriptive laboratory study | 5 | Aesthetic Surgery Journal | 10 | No |
| 2021          | Busato et al. [12] | None | Descriptive laboratory study | 5 | Cells | 27 | No |
| Device/ System used (Author) | Adipose donor site | Harvest technique and manipulation of lipoaspirate prior to insertion in device/system | Volume processed (ml) | Cell Concentration (x10^6/ml of lipoaspirate) | Cell Viability (%) | Estimated total cell yield of product (x10^6)a | Laboratory analysis used to quantify cell numbers (after device/system processing) |
|----------------------------|-------------------|----------------------------------------------------------------------------------|----------------------|---------------------------------------------|------------------|-----------------------------------------------|---------------------------------------------------------------------------------|
| Adinizer (Copcu et al. [18]) | Abdomen           | Harvested with 2.8mm diameter cannula with tumescent solution and adrenaline. Pre-dilution with saline in 50% of samples tested | 5-20                 | 1.22b                                        | 92.75b           | 1.13- 13.6 (Depending on volume used)          | Y                                                                                 |
| Adiprep (Dragoo et al. [27]) | Knee fat pad      | Harvested during arthroscopy into AquaVage system. Then subjected to fractionation and syringe emulsification. | 30                   | 0.486c                                       | 69.03c           | 0.99 (Mean)                                  | Y Y Y                                                                            |
| Fastem (Domenis et al. [24]) | Abdomen, hips and trochanter region | Harvesting procedure not mentioned. ‘Standardised procedural protocol’ not described. | No data              | 0.444 to 1d                                  | -                | N/A Y                                        | Y Y Y                                                                            |
| Fastem and MyStem (Gentile et al. [29]) | No data | Harvesting procedure not mentioned. | 80 10                | 0.03 and 0.005                               | 98c              | 0.29 and 0.049                               | Y Y Y                                                                            |
| Device/ System used (Author) | Adipose donor site | Harvest technique and manipulation of lipoaspirate prior to insertion in device/system | Volume processed (ml) | Final volume of product (ml) | Cell Concentration (x10^6/ml of lipoaspirate) | Cell Viability (%) | Estimated total cell yield of product (x10^6) | Laboratory analysis used to quantify cell numbers (after device/system processing) |
|-----------------------------|-------------------|-----------------------------------------------------------------|----------------------|-----------------------------|---------------------------------|------------------|---------------------------------|-----------------------------------------------------------------|
| Hy-Tissue SVF (Busato et al. [12]) | Abdomen | Harvested with 11G cannula with Klein tumescence solution, followed by decantation | 25-30 | No data | 0.041 | - | N/A | Y |
| Lipocube Nano & Tulip Nanotransfer (Cohen et al. [17]) | No data | Harvested with 2.4mm diameter cannula and then cleaned with Ringer's lactate, sedimented and decanted | 10 | No data ('Pellet' used) | 2.24 and 1.44 | 96.05 | N/A | Y |
| Lipocube SVF (Tiryaki et al. [50]) | Hip | Harvested with 3.5mm diameter cannula then decanted | 20 | No data ('Pellet' used) | 0.94 | 97.55 | N/A | Y |
| Lipogems (Vezzani et al. [75]) | Abdomen | Harvested with 17G cannula either manually or vacuum assisted and mixed with saline | 60 | 20-30 | 0.027 | - | N/A | Y |
| Lull pgm (Morselli et al. [42]) | Abdomen | Harvesting procedure not mentioned. ‘Negative pressure’ not clarified | 30 | 10 | 2.4 | - | N/A | Y |

* *

Table 3 (continued)

| Device/ System used (Author) | Adipose donor site | Harvest technique and manipulation of lipoaspirate prior to insertion in device/system | Volume processed (ml) | Final volume of product (ml) | Cell Concentration (x10^6/ml of lipoaspirate) | Cell Viability (%) | Estimated total cell yield of product (x10^6) | Laboratory analysis used to quantify cell numbers (after device/system processing) |
|-----------------------------|-------------------|-----------------------------------------------------------------|----------------------|-----------------------------|---------------------------------|------------------|---------------------------------|-----------------------------------------------------------------|
| Hy-Tissue SVF (Busato et al. [12]) | Abdomen | Harvested with 11G cannula with Klein tumescence solution, followed by decantation | 25-30 | No data | 0.041 | - | N/A | Y |
| Lipocube Nano & Tulip Nanotransfer (Cohen et al. [17]) | No data | Harvested with 2.4mm diameter cannula and then cleaned with Ringer's lactate, sedimented and decanted | 10 | No data ('Pellet' used) | 2.24 and 1.44 | 96.05 | N/A | Y |
| Lipocube SVF (Tiryaki et al. [50]) | Hip | Harvested with 3.5mm diameter cannula then decanted | 20 | No data ('Pellet' used) | 0.94 | 97.55 | N/A | Y |
| Lipogems (Vezzani et al. [75]) | Abdomen | Harvested with 17G cannula either manually or vacuum assisted and mixed with saline | 60 | 20-30 | 0.027 | - | N/A | Y |
| Lull pgm (Morselli et al. [42]) | Abdomen | Harvesting procedure not mentioned. ‘Negative pressure’ not clarified | 30 | 10 | 2.4 | - | N/A | Y |

* *
| Device/System used (Author) | Adipose donor site | Harvest technique and manipulation of lipoaspirate prior to insertion in device/system | Volume processed (ml) | Volume of product (ml) | Cell Concentration (x10⁶/ml of lipoaspirate) | Cell Viability (%) | Estimated total cell yield of product (x10⁶) | Laboratory analysis used to quantify cell numbers (after device/system processing) | Enzyme use | Centrifugation | Filtration | Washing | Other Mechanical | Culture medium/FBS/Antibiotic | Counting Device |
|-----------------------------|-------------------|--------------------------------------------------------------------------------|---------------------|----------------------|---------------------------------------------|------------------|-------------------------------------------|-------------------------------------------------|----------|---------------|-----------|----------|----------------|-----------------------------|---------------|
| MyStem (Cicone et al. [16])| No data           | Harvested with MyStem 1.8mm blunt-tip cannula. Process not reported.           | 17-50               | 8-23.5 (Variable)    | 0.6                                         | 75.87                        | 3.6-10.7 (Depending on introduced volume) | Y                                               | Y        |               |           |          |                |                             | NucleoCounter |
| MyStem (Tarallo et al. [65])| Abdomen           | Harvested with local anaesthetic. Standard protocol not described             | 30                  | 1-7 (Variable)      | 0.83                                        | 74.3                          | 0.62-4.3         | Y       Y                                           | Y        |               |           |          |                |                             | NucleoCounter |
| Puregraft (Streit et al. [63])| Abdomen           | Harvested with 3.5mm diameter cannula with tumescent solution.                | 50                  | No data (Pellet used)| 0.198                                       | 60                            | N/A                        | Y       Y                                           | Y        |               |           |          |                |                             | Haemocytometer |
| Rigenera (Dai Pre et al. [20])| Thigh and Abdomen | Harvesting procedure not mentioned. Lipoaspirate mixed with equal volume of culture medium, FBS and antibiotics. | 4                   | 4                    | 21                                          | -                             | N/A                        | Y       Y                                           | Y        |               |           |          |                |                             | Tryptan blue exclusion assay |
| Transpose RT (Winner et al. [77])| No data           | Harvested with standard procedure - not described. Lipoaspirate mixed with lactated Ringer solution | 25                  | 3                    | 0.084                                       | 61.7                          | 0.16                        | Y       Y                                           | Y        |               |           |          |                |                             | NucleoCounter |
Table 3 (continued)

| Device/ System used (Author) | Adipose donor site | Harvest technique and manipulation of lipoaspirate prior to insertion in device/system | Volume processed (ml) | Final volume of product (ml) | Cell Concentration (x10⁶/ml of lipoaspirate) | Cell Viability (%) | Estimated total cell yield of product (x10⁶)ᵃ | Laboratory analysis used to quantify cell numbers (after device/system processing) | Enzyme use | Centrifugation | Filtration | Washing | Other Mechanical | Culture medium/FBS/Antibiotic | Counting Device |
|-----------------------------|--------------------|---------------------------------------------------------------------------------|----------------------|-----------------------------|--------------------------------------------|-------------------|---------------------------------------------|---------------------------------------------------------------------------------|----------|----------------|------------|---------|----------------|--------------------------|----------------|
| Tulip Nanotransfer (Sese et al. [61]) | Abdomen | Harvested with Carraway Harvester cannula with tumescent fluid, then washed with saline. | 20 | 10 | 6.63 | 76.8 | 50.9 | Y | Y | NucleoCounter |

ᵃ Estimated total cell yield = Volume of product (ml) X Cell concentration (x10⁶/ml of lipoaspirate) X % Cell viability
ᵇ Value given is an average obtained from the four different protocols used in the study
ᶜ Figures from Layer 2 which resulted in the highest numbers
ᵈ Enrichment performed in only 50% of lipoaspirate sample
ᵉ Generalised figure for the study overall, not specific to either device/system
| Device/System used (Author) | Type of immuno-phenotypic analysis of cell subtypes | Terminology for uncultured, freshly isolated cells | Stage of cell processing | Positive cell CD marker expression (%) | Mesenchymal stem cell markers | Endothelial cell, pericyte and haematopoetic markers |
|-----------------------------|-----------------------------------------------|---------------------------------------------------|-------------------------|----------------------------------------|-------------------------------|--------------------------------------------------|
| Adinizer (Copcu et al. [18]) | Flow Cytometry | Stromal cells/Nuclear cells | Immediately after device use (minimally manipulated) | 56.5 72.0 60.4 65.2 33.4 80.3 | CD13 CD29 CD44* CD73 CD90* CD105* CD146* | CD31 CD34 CD45 CD68 Other |
| Adiprep (Dragoo et al. [27]) | Flow Cytometry | SVF Cells | Immediately after device use (minimally manipulated) | 56.5 72.0 60.4 65.2 33.4 80.3 | CD13 CD29 CD44* CD73 CD90* CD105* CD146* | CD31 CD34 CD45 CD68 Other |
| Fastem (Domenis et al. [24]) | Flow Cytometry | SVF Cells | Immediately after device use (minimally manipulated) | 50-60 | CD34+CD45-CD31-10-20 | CD34+CD45-CD31-20-30 |
| Fastem and MyStem (Gentile et al. [29]) | Not done | SVF Nucleated Cells | No control | 0-10 | CD34+CD45-CD31-20-30 | CD34+CD45-CD31-20-30 |

As per methods: Proportions of CD45 negative cells were analysed in CD34–CD146+ and CD34+CD146–CD90+ (deemed as regenerative perivascular cells), and CD34+CD146+ as endothelial cells. However, percentages not specifically reported in results.
| Device/System used (Author) | Type of immunophenotypic analysis of cell subtypes | Terminology for uncultured, freshly isolated cells | Stage of cell processing | Positive cell CD marker expression (%) |
|----------------------------|-----------------------------------------------|-----------------------------------------------|--------------------------|-------------------------------------|
|                            |                                               |                                               |                          | **Mesenchymal stem cell markers** |
|                            |                                               |                                               |                          | *CD markers observed in Pericytes as well* |
|                            |                                               |                                               |                          | **Endothelial cell, pericyte and haematopoetic markers** |
|                            |                                               |                                               |                          | CD 13 | CD 29 | CD 44* | CD 73 | CD 90* | CD 105* | CD 146* | CD 31 | CD 34 | CD 45 | CD 68 | Other |
| Hy-Tissue SVF (Busato et al. [12]) | Flow Cytometry | Free nucleated SVF cells | Immediately after device use (minimally manipulated) | CD 13 | 7.61 | 6.28 | 2.6 | 9.91 | 5.5 | 3.5 | CD 116 0.7 |
|                            |                                               |                                               | Control enzymatic digestion using 0.1% collagenase type I at 37 °C for 45 min followed by centrifugation at 400G for 10 min. | CD 13 | 10.1 | 9.98 | 3.67 |
|                            |                                               |                                               | Passage in culture following device (extensively manipulated) | CD 13 | 90 | >90 | >70 | 60 | 90 |
| Lipocube Nano (Cohen et al. [17]) | Flow Cytometry | SVF Cells | Immediately after device use (minimally manipulated) | CD 13 | 42.0 | 53 | 55.8 | 53.2 | 18.8 |
| Device/ System used (Author) | Type of immuno-phenotypic analysis of cell subtypes | Terminology for uncultured, freshly isolated cells | Stage of cell processing | Positive cell CD marker expression (%) |
|-----------------------------|----------------------------------------------------|--------------------------------------------------|--------------------------|----------------------------------------|
| Lipocube SVF (Tiryaki et al. [66]) | Flow Cytometry | Nucleated SVF Cells | Immediately after device use (minimally manipulated) | CD 13 CD 29 CD 44* CD 73 CD 90* CD 105* CD 146* |
|                              |                      |                                                  |                          | CD 31 CD 34 CD 45 CD 68 Other |
|                              |                      |                                                  |                          | 21.5 6.16 11.4 9.0 |
|                              |                      |                                                  |                          | Control- enzymatic digestion using GMP grade collagenase NB6 at a concentration of 0.1 U/ml at 37 °C for 30min followed by centrifugation at 400G for 10min. Then washed with PBS solution and centrifuged at 300G for 5min. Passage in culture following device (extensively manipulated) |
|                              |                      |                                                  |                          | CD146+CD34 33.5 |
|                              |                      |                                                  |                          | CD34+CD146 5.46 |
| Lipogems (Vezzani et al. [75]) | Flow Cytometry | SVF Nucleated Cells | Immediately after device use (minimally manipulated) | CD 14 CD 31 CD 40 ligand (CD154) significantly more abundant than when compared to control. |
|                              |                      |                                                  |                          | CD146+CD34 8.39 |
|                              |                      |                                                  |                          | CD34+CD146 51.5 |
| Lull pgm (Morselli et al. [42]) | Not done | SVF Cells | No control | CD14, CD31, CD40 ligand (CD154) significantly more abundant than when compared to control. |
| Device/System used (Author) | Type of immunophenotypic analysis of cell subtypes | Terminology for uncultured, freshly isolated cells | Stage of cell processing | Positive cell CD marker expression (%) | Mesenchymal stem cell markers | Endothelial cell, pericyte and haematopoetic markers |
|----------------------------|-----------------------------------------------|-------------------------------------------------|------------------------|-------------------------------------|-----------------------------|---------------------------------|
|                            |                                               |                                                 |                        | CD 13    | CD 29 | CD 44* | CD 73 | CD 90* | CD 105* | CD 146* | CD 31 | CD 34 | CD 45 | CD 68 | Other |
| MyStem (Cicione et al. [16]) | Flow Cytometry                                 | Liposarpirate fluid cells                       | Immediately after device use (minimally manipulated) | <0.1     | 1-1.5 | <0.1   | 0.5-1 | <0.5   | <1     |                   |                   |                   |
|                            |                                               |                                                 | Control- centrifugation ‘as previously described’ | <0.1     | 1.5-2 | <0.1   | 1     | <0.5   | <0.5   |                   |                   |
|                            |                                               |                                                 | Passage in culture following device (extensively manipulated) | 93     | 98    | 95     | 96    |                     |                   |
| MyStem (Tarallo et al. [65]) | Flow Cytometry                                 | Freshly isolated LAF Cells                      | Immediately after device use (minimally manipulated) | 0-10    | 75    | 0-10   | 0-10  | 20     |                     | CD31 30                |
|                            |                                               |                                                 | No control                                                       |                   |                   |                   |                   |
|                            |                                               |                                                 | Passage in culture following device (extensively manipulated) | All culture-expanded cells displayed an ASC-like immunophenotype: CD105+, CD73+, CD90+, CD45- and CD34-CD31. |
| Puregraft (Streit et al. [63]) | Direct Immunofluorescence                      | SVF Cells                                       | Immediately after device use (minimally manipulated) | Analysed adhesive properties to determine stem cell nature. | All adherent cells were positive for CD90 and CD105 and negative for CD31 and CD45 antigens (stem cell marker). Numbers not specified. |                   |
|                            |                                               |                                                 | Control 1- aliquot was left at 37°C for 20 min under the action of gravity (decantation). |                   |                   |                   |                   |
|                            |                                               |                                                 | Control 2- aliquot centrifuged at 1200G for 3 min. |                   |                   |                   |                   |
|                            |                                               |                                                 | Passage in culture following device (extensively manipulated) |                   |                   |                   |                   |
| Device/System used (Author) | Type of immuno-phenotypic analysis of cell subtypes | Terminology for uncultured, freshly isolated cells | Stage of cell processing | Positive cell CD marker expression (%) |
|-----------------------------|-------------------------------------------------|-------------------------------------------------|--------------------------|----------------------------------------|
| Rigenera (Dai Pre et al. [20]) | Flow Cytometry | Total cells | Immediately after device use (minimally manipulated) | CD13 4.98 CD29 3.12 CD44$^*$ 30.4 CD73 16.6 CD90$^*$ 16.6 CD105$^*$ 16.6 CD146$^*$ 278 |
| | | | Control-enzymatic digestion using 0.1% collagenase type I at 37°C for 45 min in Hank’s Balanced Salt Solution (HBSS) and 2% bovine serum albumin followed by centrifugation at 3000 rpm for 7 min. | |
| | | | Passage in culture following device (extensively manipulated) | Expression of the typical mesenchymal stem cell markers (CD105, CD90, CD73, CD44, and CD29) and the hematopoietic markers (CD45 and CD34) was preserved through culture passages. | |
| Transpose RT (Winnier et al. [77]) | Not done | Adipose-derived regenerative cells | | |
| Tulip Nanotransfer (Cohen et al. [17]) | Flow Cytometry | SVF Cells | Immediately after device use (minimally manipulated) | 18.3 50 42.1 24.1 7.9 |
| | | | No control | |
| | | | Passage in culture following device (extensively manipulated) | |
| Tulip Nanotransfer (Sese et al. [61]) | Not done | Nanofat cells | | |

*CD markers observed in Pericytes as well*
| Device/System | Company and location | Level of automation | Processing Time (mins) | Mechanical techniques used by device/system | Clinical Applications in PubMed indexed studies |
|---------------|----------------------|---------------------|------------------------|---------------------------------------------|-----------------------------------------------|
| Adinizer      | BSLrest, Busan, South Korea | Manual | Variable (operator dependent) | Y | Indication: Fat grafting/Lipofilling Treatment: [18] Cellular product applied at varying depths to different aesthetic units of the face in 24 patients. Outcome: Visual analog scale (VAS) scores at 2 years were consistently high (Range 6-9) from both patient and surgeon. |
| Adiprep system (+ Smartprep) | Harvest Technologies Corp. Plymouth, MA, USA | Manual + Automated | 4 | Y | Emulsification | None |
| Fastem        | CORIOS Soc. Coop, Milan, Italy | Automated | 10 | Y | Y | Indication: Fat grafting Treatment: [24] Cellular product used to enrich fat grafts before breast augmentation in six patients, comparing their clinical results with patients who underwent grafting with standard liposaprate (n=16). Outcome: Greater gain of thickness of both the central and superior-medial quadrants at 6 months vs control. |
| Hy- Tissue SVF | FidiaFarmaceutici S.p.A, Padua, Italy | Manual | 15 | Y | Y | Massage |
| Lipocube Nano | Lipocube Inc, London, UK | Manual | 20-30 | Y | Y | Emulsification | None |
| Lipocube SVF/ CellDrive | Lipocube Inc, London, UK | Manual + Automated | 20-30 | Y | Y | Y | Indication: Fat grafting Treatment: [67] SVF cell-enriched fat grafting in 46 patients for various aesthetic and reconstructive applications. Outcome: No complications. Results on a 4-point patient satisfaction scale ranged from good to excellent. |
Table 5 (continued)

| Device/ System | Company and location | Level of automation | Processing Time (mins) | Mechanical techniques used by device/system | Clinical Applications in PubMed indexed studies |
|----------------|----------------------|---------------------|------------------------|---------------------------------------------|-----------------------------------------------|
| Lipogems       | Lipogems Interna- tional S.p.A, Milan, Italy | Semi-automated | 3-5 | Y | Y | Y | Shaking, Emulsification |
|                |                      |                     |                        | Centrifugation | Filtration | Cutting / Mincing | Sedimentation / Decantation | Washing | Other (Specify) |

**ENT**
- **Indication:** Vocal cord palsy
- **Treatment:** [54]: 3 patients had laryngoplasty and injection of autologous cellular product.
- **Outcome:** At 12-month follow-up period, voice improvement was consistent in all patients.

**General Surgery**
- **Indication:** Intersphincteric anal lipofilling
- **Treatment:** [15]: 3 patients with faecal incontinence had autologous cellular product injected in the intersphincteric anal groove.
- **Outcome:** At 1 month post procedure, each patient had an improved Wexner incontinence score. At 6 months, ano-rectal manometry showed an increase of resting pressure and ultrasound showed increased thickness of the sphincter.

**Indication:** Repair of a vesicouterine fistula
- **Treatment:** [62]: 1 patient had endoscopic transurethral resection of the fistulous tract and injection of autologous cellular product.
- **Outcome:** 3 months post procedure, patient was asymptomatic. Cystoscopy showed appropriate scar tissue and cystogram revealed complete repair of VUF. At 24 months, there were no recurrences.

**Orthopaedic Surgery**
- **Indication:** Osteoarthritis
- **Treatment:** [7]: 20 patients with knee OA were injected with autologous cellular product and followed up at various intervals.
- **Outcome:** Improvements in Knee injury and Osteoarthritis Outcome Score (KOOS) were significant at 3-, 6- and 12-months follow-up. At one year, there were improvements in KOOS pain = 14 points, symptoms = 7, activities of daily living = 13, sports = 19 and quality of life = 15.
- **Treatment:** [76]: 25 patients with shoulder OA were injected with autologous cellular product and followed up at various intervals.
- **Outcome:** At one-year, significant improvement (p<0.001) in Visual Analog Scale and disabilities of the arm.
| Device/System | Company and location | Level of automation | Processing Time (mins) | Mechanical techniques used by device/system | Clinical Applications in PubMed indexed studies |
|---------------|----------------------|---------------------|------------------------|---------------------------------------------|-----------------------------------------------|
|               |                      |                     |                        | Centrifugation Filtration Cutting / Mincing | Treatment [21]: 6 consecutive patients with hip OA were given single intra-articular injection of autologous cellular product and followed up at 6 months. Outcome: Harris Hip Score improved from 67.2 (mean pre-operative value) to 84.6 (mean post-operative value) |
|               |                      |                     |                        | Sedimentation/ Decantation Washing Other (Specify) | Treatment [47]: 17 patients with knee OA treated with ultrasound-guided intra-articular injection of autologous cellular product and followed up for up to 12 months. Outcome: Knee Society Score improved from average 74 (baseline) to 82 (12 months) |
|               |                      |                     |                        |                                              | Treatment [59]: 20 patients with temporomandibular OA treated with autologous cellular product after arthrocentesis vs control group (hyaluronic acid instead). Follow up for up to 6 months. Outcome: Treatment group had a statistically significant superiority in the success rate compared with the control group (P = 0.018). |
|               |                      |                     |                        |                                              | Treatment [72]: 64 patients with symptomatic mild-severe knee OA treated with autologous cellular product. Follow up for up to 12 months. Outcome: KOOS, NRS and EQ-5D improved significantly at follow-up compared to baseline (p < 0.05). |
|               |                      |                     |                        |                                              | Treatment [57]: 52 patients with early knee OA treated with autologous cellular product after arthroscopic debridement. Follow up for up to 24 months. Outcome: The IKS function score improved from average 57.7 (pre-operatively) to 83.0 (at the latest follow-up) (p<0.01). |
|               |                      |                     |                        |                                              | Treatment [73]: 23 patients with early to moderate patellofemoral OA treated with autologous cellular product. Mean follow-up was 22.1 months. Outcome: Significant improvements in mean IKS knee and function scores vs baseline (35.6 to 61.9 and 52.0 to 82.3 respectively). |
|               |                      |                     |                        |                                              | Treatment [58]: 202 patients with OA (Kellgren-Lawrence I-IV) were injected with autologous cellular product. Mean follow-up was 24.5 months. |


**Table 5** (continued)

| Device/ System | Company and Location | Level of automation | Processing Time (mins) | Mechanical techniques used by device/system | Clinical Applications in PubMed indexed studies |
|-----------------|----------------------|---------------------|------------------------|---------------------------------------------|------------------------------------------------|
|                 |                      |                     |                        | Centrifugation | Filtration | Cutting / Mincing | Sedimentation / Decantation | Washing | Other (Specify) |                                                      |
| **Outcome:**    | At 6 months, Total KOOS significantly improved from baseline (p 0.001) and between 6-12 months. At 16 months, VAS was reduced vs baseline (p 0.001), increased at 12 months but remained below baseline. |
| **Indication:** | Used with High Tibial Osteotomy (HTO) for correction of varus knee OA |
| **Treatment:**  | (36) 42 patients treated with HTO and simultaneous intra-articular injection of cellular product vs 43 patients treated with only HTO |
| **Outcome:**    | No significant results between both treatment groups in terms of KOOS pain, symptoms, sports, and quality of life. However, a significant improvement (p<0.05) in the activities of daily living. |
The Oxford Centre for Evidence-Based Medicine (OCEBM) checklist [80] for therapeutic studies was used to assess the level of evidence of the included studies. Quality review of the studies was performed using a modified ‘Minimum Information for Studies Evaluating Biologics in Orthopaedics (MIBO)’ checklist presented by Murray et al. [45], which has been designed specifically for MSC-related studies. Adaptations from the STROBE assessment tool [19] were incorporated for assessing study design. A ‘heat map’ of reporting was subsequently generated (Fig. 3). The tool was validated by the same two reviewers (PL and BG) independently analysing the various domains.

Results

Search results
From the primary search 11 studies fulfilled the inclusion criteria. Four additional studies were identified through other means (n = 3 through references, n = 1 additional search), leaving a total of 15 studies for qualitative synthesis (Fig. 2) [40]. Emailing the manufacturers for additional information resulted in five responses (BSLrest- Adinizer, Harvest Technologies Corp- Adiprep + SmartPrep, Tulip Medical- Tulip Nanotransfer, Cytori Therapeutics- Puregraft and Fidia Farmaceutici S.p.A- Hy-Tissue SVF). No new articles for inclusion were identified by these means, but some were used to populate Table 5.

Level of evidence
Most of the included studies were low level evidence (Table 2) [12, 16–18, 20, 24, 27, 29, 42, 61, 63, 65, 66, 75, 77] 11 were Level 5 [12, 16, 17, 20, 27, 42, 61, 63, 66, 75, 77] (descriptive laboratory studies), one was Level 4 [18] and only three were Level 2 [24, 29, 65].

Quality Assessment (Fig. 3)
All included studies [12, 16–18, 20, 24, 27, 29, 42, 61, 63, 65, 66, 77] disclosed whether they had any financial or other competing interests. 73.3% (n = 11/15 [12, 17, 20, 24, 27, 29, 42, 61, 63, 66, 77]) gave a clear objective which reduced the risk of outcome bias. 26.6% (n = 4/15 [17, 18, 27, 77]) lacked an adequate control group which may have resulted in interpretation bias or publication bias. Most red fields in the heat map were for the ‘Donor details’ and...
‘Tissue harvesting’ domains. Notably, only one study [24] reported donor co-morbidities, one [20] reported the media for tissue storage following harvest, and one [12] the time between tissue harvest and processing.

### Cell concentrations

All studies reported a concentration for freshly isolated cells following harvest and device/system administration (Table 3). There were varying definitions for these heterogeneous minimally manipulated cells, the most common term that was used was ‘SVF cells’ ($n=9$) (Table 4).

Dai Pre et al. [20] reported the highest concentration achievable ($21 \pm 0.16 \times 10^6$ per ml/ lipoaspirate) using the device/system Rigenera. For all devices/systems, mean concentration was $2.30 \times 10^6$/ml overall $\pm 4.92 \times 10^5$ (standard deviation). The next highest concentrations were Sese et al. [61] ($6.63 \pm 0.47 \times 10^6$/ml- Tulip Nanotransfer), Morselli et al. [42] ($2.4 \times 10^6$/ml- Lull pgm) and Cohen et al. [17] ($2.24 \times 10^6$/ml and $1.44 \times 10^6$/ml- Lipocube Nano & Tulip Nanotransfer) accordingly.

### Cell viability

Only two thirds of the studies ($n=10$) [16–18, 27, 29, 61, 63, 65, 66, 77] gave a cellular viability in conjunction with their concentration (Table 3), the highest being Gentile et al. [29] with 98% using Fastem and Mystem. However, this viability figure was quoted for both devices overall rather than a specific one for each of the device’s products. The next highest figure was 97.55% for Tiryaki et al. [66] using Lipocube SVF.

For devices/systems with an associated viability figure, mean viability was $80.2\% \pm 14.0\%$ (standard deviation). The study with the highest cell number with a viability over 90% was Cohen et al. [17] using Lipocube Nano and Tulip Nanotransfer (Fig. 4).
Immuno-phenotypic analysis

Ten studies [12, 16–18, 20, 24, 27, 65, 66, 75] used flow cytometry analysis to immuno-phenotype the cell subtypes, whereas one [63] opted for direct immunofluorescence (Table 4). Positive mesenchymal stem cell markers of CD73, CD90 and CD105 (as specified by the ISCT-International Society for Cellular Therapy [25]), as well as CD44 and CD146 (also found in pericytes [6]) were reported at varying degrees across all studies. Six studies [12, 16, 17, 27, 65, 66] reported percentages for at least one of these markers in their population of cells following device/system use.

The devices/systems with the highest percentages of MSC CD markers following minimal manipulation were Adiprep- Dragoo et al. [27] (CD73 60.4%, CD90 65.2%, CD105 33.4%), Lipocube Nano- Cohen et al. [17] (CD73 53%, CD90 55.8%) and Tulip Nanotransfer- Cohen et al. [17] (CD73 50%, CD90 42.1%).

Six studies [12, 16, 20, 24, 63, 66] performed immunophenotypic analysis on a control method as well (either enzymatic or mechanical); two [24, 63] for mechanical, with a large difference only observed with Fastem [24].

Three studies [12, 16, 27] performed analysis of the MSC phenotype following culture and consistently achieved above 90% for CD markers 73,90,105.

Devices/systems and their individual characteristics

Out of the 15 studies, 13 unique mechanical devices and systems were identified (Table 5). Five were manufactured by companies in the USA and four in Italy. Traditionally, the mechanical processes used have been centred around three main techniques: decantation, centrifugation and filtration [8]. More novel methods have now been introduced including the physical disruption of tissue, washing and cutting. The most popular techniques adopted were filtration (n = 10), washing (n = 5) and cutting/ mincing (n = 5).

Clinical applications

Only four of the included studies [18, 24, 29, 65] assessed clinical outcomes following the use of their device/systems (Table 2). Copcu [18], Domenis [24] and Gentile [29] reported positive outcomes following contouring procedures. Tarallo [65] reported wound healing improvement using MyStem EVO.

Other clinical applications have been highlighted in Table 5 [7, 15, 21, 22, 33–39, 47, 51, 54, 55, 57–59, 62, 67, 71–73, 76]. None of the authors reported the constituents of the cellular therapies used in these studies. Lipogems [7, 21, 36, 47, 57–59, 72, 73, 76], MyStem EVO [55] and Hy-Tissue SVF [71] were the only device/systems to have been used in orthopaedic application.

Discussion

This scoping review identified 13 unique mechanical devices/systems from 15 articles that fulfilled the inclusion criteria. The mean cell concentration (cell number generated per millilitre of processed lipoaspirate) from these devices/systems was $2.30 \times 10^6$/ml of lipoaspirate (Table 3). Ten of 15 studies gave a cellular viability in conjunction with their concentration (mean 80.2%). 11 studies performed immuno-phenotypic analysis to characterise cell-types (Table 4), with six reporting markers for MSCs. Four studies assessed clinical outcomes. Only two studies [18, 65] reported all four parameters.
The mean cell concentration ($2.30 \times 10^6$/ml) was higher than concentrations obtained by conventional mechanical methods not using a POC device/system, as shown by Aronowitz et al. [4] (0.01–0.24 \times 10^6). It is possible that concentrations are greater following device/system use because of reduced handling and processing times. Nonetheless, this figure was skewed by one study [20] which did not report cell viability.

Viability is the proportion of live and metabolically active cells in the sample, so POC devices/systems should aspire for a cell viability as close to 100% as possible. The International Federation for Adipose Therapeutics and Science (IFATS) has since proposed a minimum threshold of 70% [10] for cells, but this was to allow for good cell expansion. Only nine devices/systems (seven studies) reported a cell viability above 70% [16–18, 29, 61, 65, 66]. Of these, the mean cell concentration was $1.55 \times 10^6$ (0.005–6.63 \times 10^6). This was still higher than that of previously published literature [4], which indicates the therapeutic promise that these POC devices/systems may present.

However, this places significant weight on cell concentration as a variable. The cell yield (total number of cells delivered to the patient) is affected by the volume of the final product, as well as cell concentration. This varies across studies (Table 3) and depends on the therapeutic indication that is required. Additionally, evidence for a correlation between cell number and observed clinical benefit is inconclusive at present [50]. Theoretically, higher cell concentrations should result in higher ASC numbers (when accounting for the final volume of product) and therefore better outcomes, but this hypothesis is making the assumption that ASCs are the critical cell type in achieving clinical benefit. If so, the most effective devices/systems were the Tulip Nanotransfer which isolated $6.63 \times 10^6$ cells/ml at 76.8% viability and Lipocube Nano- $2.24 \times 10^6$ cells/ml at 96.05% viability; the highest concentrations and viability combined (Fig. 3). These devices/systems utilise filtration and cutting/mincing in their processing, and avoid other steps such as centrifugation, sedimentation and washing, hence the terms microfragmented adipose tissue (MFAT) or nanofat [31] being used in the literature to describe the processed lipoaspirate.

On the other hand, there was variability in the concentrations obtained from these devices/systems [17, 61] and others across different studies. Therefore, it is unclear whether the higher concentrations obtained overall were significant or erroneous. It is likely that such variation was due to the lack of standardisation in the preparation methods and laboratory analysis (Table 3). Variability was also observed intra study with Dai Pre et al. [20] demonstrating that harvesting site could affect cell concentration. In this study, it appeared that lipoaspiration from the thigh resulted in higher cell numbers than the abdomen [20]. This is a key observation when considering the different donor sites across our studies (Table 3). However, more work is required to confirm these findings and establish the best location. Publications have shown other influential factors to be patient demographics [26], harvesting technique [2, 41] and volume processed [68]. The reporting of these factors is variable and has been highlighted in the quality review of studies (Fig. 3). Such non-reproducible results affect the reliability of the concentrations and the subsequent conclusions that can be drawn.

In addition to cell concentration and viability, six studies undertook MSC surface marker analysis to confirm the presence of ASCs within the therapies obtained [12, 16, 17, 27, 65, 66]. The Adiprep system [27] had the highest proportion of MSC CD markers (CD73 60.4%, CD90 65.2%, CD105 33.4%), with Lipocube Nano and Tulip Nanotransfer second and third [17] (CD73 53%, CD90 55.8% and CD73 50%, CD90 42.2% respectively). Despite these results, these studies did not have suitable control methods for comparison (Table 4). Again, these markers only hold particular importance if ASCs are the therapeutic cell type. New information suggests that the other cells within the niche, including: preadipocytes, endothelial cells, macrophages and T-Cells [9, 11], may be just as important (as the ASCs/MSCs act in a paracrine manner). Reporting of these cell subtypes other than just MSCs alone would help us understand the basic science better.

Although these studies have focussed on the cells generated, other authors have highlighted the regenerative capabilities of the cell-free components in processed lipoaspirate. Sarkanen et al. [56] showed that adipogenesis could be induced by using cell-free extract of adipose tissue, possibly due to extracellular vesicles (membrane-bound phospholipids found in the lipoaspirate fluid) [46]. Other factors that could be important include: lipids, RNA, miRNA, DNA, soluble factors and other signalling molecules and proteins, all of which play a role in regulating biological behaviour and immunomodulation [56]. Consideration of using protein assays and other focussed analytical techniques in future studies for these molecules would be useful.

We are still at a juvenile stage in understanding the basic science for these minimally manipulated products, especially given the cellular heterogeneity, small number of ASCs and extracellular components involved. Therefore, improved reporting of their composition is needed so that we can correlate the cellular and molecular components that are present in these therapies with clinical gain [49, 52]. As this review
highlights, there is a paucity of studies (four [18, 24, 29, 65]) that have reported not only cellular composition data adequately, but corresponding clinical outcomes as well. Interestingly, these studies were for cosmetic purposes only. The trophic properties of uncultured cells from processed lipoaspirates have been well reported [64], so the use of these POC devices/systems in the aesthetic industry has gained particular traction.

Other publications have reported clinical outcome data alone from using these POC devices/systems (Table 5), but only Lipogems [7, 21, 36, 47, 57–59, 72, 73, 76], MyStem EVO [55] and Hy-Tissue SVF [71] been used in orthopaedic related studies. Lipogems is a closed system which performs washing, filtration and sedimentation, with manual shaking and emulsification also required [74]. It has become popular in orthopaedics, having established an early patent for clinical use [68], as well as being a user-friendly system [68]. Furthermore, its marketing has generated commercial interest amongst consumers. However, as with any marketing, there is the potential for dissemination of false or overexaggerated claims, leading to misunderstanding amongst clinicians [43]. This can hinder further progress within the field. As this review has established, it is not clear what is being re.injected into patients when using these therapies, so it is important that clinicians are made aware of this for their clinical practice.

A weakness of this review is the lack of standardisation in the preparation methods and analytical techniques used across the studies. A systematic review by Robinson et al. [52], which analysed the application of MSCs in orthopaedics and sports medicine, similarly highlighted the inadequate reporting of preparation methods and composition. Standardisation of protocols to allow for fairer comparisons between studies would be helpful. Both the ‘DOSES’ tool [44] and ‘MIBO’ checklist [45] described by Murray et al. were expert consensuses for improving the transparency of cell-based therapy reporting and should be considered in all studies within the field. Another weakness is that some publications may not have been captured if the device/system name was used in the abstract instead of generic search terms (‘device’ or ‘system’). Further studies may have also been missed if they were either unpublished or in non-peer reviewed journals.

Conclusions
This review increases awareness of POC devices/systems so that users can make informed decisions about using their cellular products for treating musculoskeletal conditions. Regarding cell concentration, cell viability and MSC immunophenotypic analysis, the most effective devices/systems were the manual devices/systems utilising filtration and cutting/mincing techniques. However, it was not known whether high performance in these categories would translate to improved clinical outcomes, let alone which components of the product (cellular or non-cellular) influence the clinical results.

Due to the lack of standardisation in preparation methods and analytical techniques, as well as heterogeneity of the data, it was not possible to draw any reliable conclusions and determine the role of these devices/systems in clinical practice at present. Future studies that investigate clinical outcomes from using these POC devices/systems should improve their reporting of cellular and non-cellular composition (to help to understand the basic science better) as well as pursue minimum standard requirements for preparation protocols and laboratory analysis.

Abbreviation
OA: Osteoarthritis; MSCs: Mesenchymal stem cells; ASCs: Adipose-derived stem cells; TOST: Total stromal cells; MFAT: Microfragmented adipose tissue; SVF: Stromal vascular fraction; POC: Point-of-care; PRISMA-ScR: Preferred Reporting Items for Systematic Review and Meta-Analysis extension for scoping reviews; MeSH: Medical Subject Heading; RCTs: Randomised control trials; OCEBM: Oxford Centre for Evidence-Based Medicine; MIBO: Minimum Information for Studies Evaluating Biologics in Orthopaedics; STROBE: Strengthening the Reporting of Observational studies in Epidemiology; IFATS: International Federation for Adipose Therapeutics and Science.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s40634-022-00537-0.

Acknowledgements
The authors would like to thank Ms Potenza Atiogbe, Multi-professional Education and Library Services Manager at Epsom and St Helier’s NHS Foundation Trust, for her support and help in searching the literature and obtaining some of the full-text articles used in this review.

Authors’ contribution
PL was involved in study design, data acquisition, analysis and interpretation of data, and writing the manuscript. BG was involved in data acquisition, analysis and interpretation of data, and writing the manuscript. IA was involved in interpretation of data and writing the manuscript. MS was involved in interpretation of data and writing the manuscript. DHS was involved in interpretation of data and writing the manuscript. REF was involved in interpretation of data and writing the manuscript. IA was involved in study design, analysis and interpretation of data, and writing the manuscript. All authors read and approved the final manuscript.

Funding
The authors received no funding for this study.

Availability of data and materials
All data cited and referenced where applicable.
Declarations

Ethics approval and consent to participate
Not required.

Consent for publication
Not required.

Competing interests
The authors declare no conflict of interest relevant to the subject of this study.

Author details
1 South West London Elective Orthopaedic Centre, Epsom, UK. 2 Centre for Regenerative Medicine and Devices, School of Applied Sciences, University of Brighton, Brighton, UK. 3 University of London, St George’s, London, UK.

Received: 25 May 2022   Accepted: 15 September 2022
Published online: 09 October 2022

References
1. Adam A, Kiraz Y, Baran Y (2016) Cell Proliferation and Cytotoxicity Assays. Curr Pharm Biotechnol 17:1213–1221
2. Alexander RW, Harrell DB (2013) Autologous fat grafting: use of closed syringe microcannula system for enhanced autologous structural grafting. Clin Cosmet Investig Dermatol 6:91–102
3. Asopa V, Vincent T, Saklatvala J (2020) The Effects of Age and Cell Isolation on Collagen II Synthesis by Articular Chondrocytes: Evidence for Transcriptional and Posttranscriptional Regulation. BioMed Res Int 2020:4060135
4. Avolio E, Alvino VV, Ghorbel MT, Campagnolo P (2017) Perivascular cells Procedure Allows the Isolation of Structurally Preserved Connective Tissue-Derived Stromal/Vascular Fraction and Culture Expanded Adipose Tissue-Derived Stromal/vascular Fraction. Cells 10:36
5. Bafro KD, Bland L (2019) Treatment of osteoarthritis with autologous fat grafting. Wideochirurgia 22:373–377
6. Barfod KW, Blønd L (2019) Treatment of osteoarthritis with autologous fat grafting: use of closed syringe microcannula system for enhanced autologous structural grafting. Clin Cosmet Investig Dermatol 6:91–102
7. Aryshe H, O’Mally L (2005) Scoping studies: towards a methodological framework. Int J Soc Res Methodol 8:19–32
8. Aronowitz JA, Lockhart RA, Hakakian CS (2015) Mechanical versus enzymatic isolation of stromal vascular fraction cells from adipose tissue. Springerplus 4:713
9. Asopa V, Vincent T, Saklatvala J (2020) The Effects of Age and Cell Isolation on Collagen II Synthesis by Articular Chondrocytes: Evidence for Transcriptional and Posttranscriptional Regulation. BioMed Res Int 2020:4060135
10. Avolio E, Alvino VV, Ghorbel MT, Campagnolo P (2017) Perivascular cells Procedure Allows the Isolation of Structurally Preserved Connective Tissue-Derived Stromal/Vascular Fraction and Culture Expanded Adipose Tissue-Derived Stromal/vascular Fraction. Cells 10:36
11. Barfod KN, Bland L (2019) Treatment of osteoarthritis with autologous fat grafting. Wideochirurgia 22:373–377
12. Barfod KN, Bland L (2019) Treatment of osteoarthritis with autologous fat grafting: use of closed syringe microcannula system for enhanced autologous structural grafting. Clin Cosmet Investig Dermatol 6:91–102
13. Aronowitz JA, Lockhart RA, Hakakian CS (2015) Mechanical versus enzymatic isolation of stromal vascular fraction cells from adipose tissue. Springerplus 4:713
14. Asopa V, Vincent T, Saklatvala J (2020) The Effects of Age and Cell Isolation on Collagen II Synthesis by Articular Chondrocytes: Evidence for Transcriptional and Posttranscriptional Regulation. BioMed Res Int 2020:4060135
15. Avolio E, Alvino VV, Ghorbel MT, Campagnolo P (2017) Perivascular cells Procedure Allows the Isolation of Structurally Preserved Connective Tissue-Derived Stromal/Vascular Fraction and Culture Expanded Adipose Tissue-Derived Stromal/vascular Fraction. Cells 10:36
16. Ciccione D, Di Taranto G, Barba M, Isgrò MA, D’Allessio A, Cervelli D, Sciarretta PV, Pelo S, Michetti F, Lattanzi W (2016) In Vitro Validation of a Closed Device Enabling the Purification of the Fluid Portion of Liposuction Aspirates. Plast Reconstr Surg 137:1157–1167
17. Cohen SR, Tiryaki T, Womack HA, Canikyay S, Schlundraf KJ, Scheflan M (2019) Cellular Organization of Nanofat: Comparison of Two Nanofat Processing Devices in Terms of Cell Count and Viability. Aesthetic Surg J Open Forum 2(4):ojaa355
18. Copcu HE, Oztan S (2020) New Mechanical Fat Separation Technique: Adjustable Regenerative Adipose-tissue Transfer (ARAT) and Mechanical Stromal Cell Transfer (MEST). Aesthetic Surg J Open Forum 20(4):ojaa355
19. Cuscieri S (2019) The STR0BE guidelines Saudi J Anaesth 13:31
20. Dai P, E, Busato A, Mannucci S, Vurro F, De Francesco F, Rizzo V, Solito S, Biswas R, Bernardi P, Rizzo M, Sbarbati A (2020) In Vitro Characterization of Adipose Stem Cells Non-Enzymatically Extracted from the Thigh and Abdomen. Int J Mol Sci 21:3081
21. Dall’Oca C, Breda S, Elena N, Valenti R, Samaila EM, Magnan B (2019) Mesenchymal Stem Cells injection in hip osteoarthritis: preliminary results. Acta Biomed 90(1–S):75–80
22. Desando G, Bartolotti I, Cattini L, Tschon M, Martin L, Fini M, Schiavon A, Soranzo C, Grigolo B (2021) Prospects on the Potential In Vitro Regenerative Features of Mechanically Treated-Adipose Tissue for Osteoarthritic Care. Stem Cell Rev Rep 17:1362–1373
23. Ding DC, Shyu WC, Lin SZ (2011) Mesenchymal Stem Cells. Cell Transplant 20:3–14
24. Domenis R, Lazzaro L, Calabrese S, Mangoni D, Gallelli A, Bourkoula E, Manini I, Bergamini A, Roverso C, Beltrami CA, Beltrami AP, Cesselli D, Parodi PC (2015) Adipose tissue derived stem cells: in vitro and in vivo analysis of a standard and three commercially available cell-assisted lipotransfer techniques. Stem Cell Res Ther 6:2
25. Dominici M, Le Blanc K, Mueller L, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, Horvitz E (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8:315–317
26. Dos-Anjos Vilaboa S, Navarro-Palou M, Lull R (2014) Age influence on stromal vascular fraction cell yield obtained from human liposapnteas. Cytotherapy 16:1092–1097
27. Dragoo JL, Chang W (2017) Arthrosopic Harvest of Adipose-Derived Mesenchymal Stem Cells From the Infrapatellar Fat Pad. Am J Sports Med 45:3119–3127
28. Gage FH (1998) Cell therapy. Nature 392(6679 Suppl):18–24
29. Gentile P, Scioli MG, Orlandi A, Cervelli V (2015) Breast Reconstruction with Enhanced Stromal Vascular Fraction Fat Grafting: What Is the Best Method? Plast Reconstr Surg - Glob Open 3:e406
30. Gai Via A, McCarthy MB, de Girolamo L, Ragni E, Oliva F, Maffulli N (2018) Making Them Commit: Strategies to Influence Phenotypic Differentiation in Mesenchymal Stem Cells. Sports Med Arthrosc Rev 26:64–69
31. Han C, Xing XS (2019) Microfragmented adipose tissue and its initial application in articular disease. Chin Med J (Engl) 132:2745–2748
32. Ikebe C, Suzuki K (2014) Mesenchymal stem cells for regenerative therapy: optimization of cell preparation protocols. BioMed Res Int 2014:951512
33. Kavala AA, Turyilmaz S (2018) Autogenously derived regenerative cell therapy for venous leg ulcers. Arch Med Sci Atheroscler Dis 3:e156–e163
34. Kuka G, Epstein J, Aronowitz J, Glasgold MJ, Rogal JG, Brown W, Gerone- mus RG, Daniels EJ, Washenik K (2020) Cell enriched autologous fat grafts to follicle niche improves hair regrowth in early androgenetic alopecia. Aesthet Surg J 40(6):NP328–NP339
35. Lobascio P, Balducci G, Minafra M, Laforgia R, Fedele S, Conticchio M, Aspirates. Plast Reconstr Surg 137:1157–1167
36. Magnanelli S, Screpis D, Di Benedetto P, Natali S, Cauero A, Zorzi C (2020) Open-wedge high tibial osteotomy associated with lipogems®. Coloproctology 22:373–377
37. Maluccio N, Minafra M, Laforgia R, Fedele S, Conticchio M, Aspirates. Plast Reconstr Surg 137:1157–1167
38. Marcelloni S, Trovato L, Novarese E, Rizzo M, Graziano A (2017) Rigenera protocol in the surgical wound dehiscence: Rigenera protocol and dehisced wounds. Int Wound J 14:277–281
38. Mestak O, Sukop A, Hsieh Y-S, Moltor M, Mestak J, Matejevska J, Zarubova L (2014) Centrifugation versus PureGraft for fat grafting to the breast after breast-conserving therapy. World J Surg Oncol 12:178
39. Miranda R, Farina E, Farina MA (2018) Micrografting chronic lower extremity ulcers with mechanically disaggregated skin using a micrograft preparation system. J Wound Care 27:60–65
40. Moher D (2009) Preferred reporting items for systematic reviews and meta-analyses: the prisma statement. Ann Intern Med 151:264
41. Mojallal A, Auxenfans C, Lequeux C, Braye F, Damour O (2008) Influence of negative pressure when harvesting adipose tissue on cell yield of the stromal-vascular fraction. Biomed Mater Eng 18:193–197
42. Monselli PG, Giorgini FA, Pazzini C, Muscari C (2017) LL pneum system: A suitable technique to improve the regenerative potential of autologous fat grafting. In vitro comparison between adipose tissue processing techniques. Wound Repair Regen 25:722–729
43. Murray IR, Chahla J, Frank RM, Pizzuto NS, MandelloBaum BR, Dragoo JL, Members of the Biologics Association (2020) Rogue stem cell clinics. Bone Jt J 102-B:148–154
44. Murray IR, Chahla J, Safran MR, Krych AJ, Saris DBF, Caplan AI, LaPrade RF (2019) International Expert Consensus on a Cell Therapy Communication Tool. DOSES. J Bone Jt Surg 101:904–911
45. Murray IR, Geeslin AG, Goudie EB, Petrigliano FA, LaPrade RF (2017) Minimum Information for Studies Evaluating Biologics in Orthopaedics (MIBO): Platelet-Rich Plasma and Mesenchymal Stem Cells. J Bone Jt Surg 99:809–819
46. Nie F, Ding P, Zhang C, Zhao Z, Bi H (2021) Extracellular vesicles derived from liposaprate fluid promote fat graft survival. Adipocyte 10:293–309
47. Panchal J, Malanga G, Sheinkop M (2018) Safety and Efficacy of Percutaneous Injection of Lipogems Micro-Fractured Adipose Tissue for Osteoarthritic Knees. Am J Orthop Belle Mead NJ 47
48. Peters MDJ, Godfrey CM, Khalil H, McNeneyy P, Parker D, Soares CB (2015) Guidance for conducting systematic scoping reviews. Int J Evid Based Healthc. 13:141–146
49. Pizzuto NS, Dominici M, Long M, Pascual-Garrido C, Rodeo S, Huard J, Guicheux J, McManovich RF, Goodrich LR, Maddens S, Robey PG, Bauer TW, Barrett J, Barry F, Karli D, Chu CR, Weiss DJ, Martin I, Jorgensen C, Muschler GF (2018) Proceedings of the signature series symposium ‘Cellular therapies for orthopaedics and musculoskeletal disease proven and unproven therapies—promise, facts and fantasy’, international society for cellular therapies, montreal, canada, may 2, 2018. Cytotherapy 2018:1381–1400
50. Prodromos C, Finkle S, Rumschlag T, Lotus J (2020) Autologous mesenchymal stem cell treatment is consistently effective for the treatment of knee osteoarthritis: the results of a systematic review of treatment and comparison to a placebo group. Medicines 7:42
51. Riccio M, Marchesini A, Zingaretti N, Carella S, Senesi L, Onesti MG, Parodi M, Riccio M, Gigante A (2019) Mechanical and Enzymatic Procedures to Isolate the Stromal Vascular Fraction From Adipose Tissue: Preliminary Results. Front Cell Dev Biol 7:88
52. Robinson PG, Murray IR, West CC, Goudie EB, Yong LY, White TO, LaPrade RF (2019) Comparative technical analysis of lipoaspirate mechanical processing techniques. Wound Repair Regen 26:2000–2010
53. Santoprete S, Marchetti F, Rubino C, Bedini MG, Nasto LA, Cipolloni V, Pola Sarkanen J-R, Kaila V, Mannerström B, Räty S, Kuokkanen H, Miettinen S, Santoprete S, Marchetti F, Rubino C, Bedini MG, Nasto LA, Cipolloni V, Pola S, Sarkanen J-R, Kaila V, Mannerström B, Räty S, Kuokkanen H, Miettinen S, Vesely J, Hanfil J, Amlfi A, Amlfi A, Taranato G (2018) Liposuction Aspirate Fluid Adipose-Derived Stem Cell Injection and Secondary Healing in Fingertip Injury. A Pilot Study. Plast Reconstr Surg 142:136–147
54. Tabet CJ, Slack GC, Fan K, Wan DC, Bradley JP (2012) Fat Grafting Versus Adipose-Derived Stem Cell Therapy: Distinguishing Indications, Techniques, and Outcomes. Aesthetic Plast Surg 36:704–713
55. Tarallo M, Fino P, Ribuffo D, Casella D, Tiscani M, Spalvieri C, Lattanzi W, Di Taranto G (2018) Liposuction Aspirate Fluid Adipose-Derived Stem Cell Injection and Secondary Healing in Fingertip Injury: A Pilot Study. Plast Reconstr Surg 140:132–140
56. Tiryaki KT, Cohen S, Kocak P, Canikyan Turkay S, Hewett S (2020) In Vitro Comparative Examination of the Effect of Stromal Vascular Fraction Isolated by Mechanical and Enzymatic Methods on Wound Healing. Aesthet Surg J 40:1232–1240
57. Tiryaki T, Ondré-Green A, Cohen SR, Canikyan S, Kocak P (2020) A 3-step Mechanical Digestion Method to Harvest Adipose-Derived Stromal Vascular Fraction. Plast Reconstr Surg Glob Open 8:e2652
58. Tremolada C, Colombo V, Ventura C (2016) Adipose Tissue and Mesenchymal Stem Cells: State of the Art and Lipogems® Technology Development. Curr Stem Cell Rep 2:304–312
59. Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, Moher D, Peters MDJ, Horsley S, Weeks L, Hempel S, Akk EA, Chang C, McGowan J, Stewart L, Hartling L, Aldcroft A, Wilson MG, Garrity C, Levins S, Goodfrey CM, Macdonald RJT, Langlois EV, Soares-Weiser K, Moirarity J, Clifford T, Tuncalp-O, Straus SE (2018) PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med 169:467–473
60. Trivisonno A, Alexander RW, Baldan S, Cohen SR, Di Rocco G, Gentile P, Magalon G, Magallon J, Miller BP, Womack H, Toietta G (2019) Intraoperative Strategies for Minimal Manipulation of Autologous Adipose Tissue for Cell- and Tissue-Based Therapies: Concise Review. STEM CELLS Transl Med 8:1265–1271
61. Usuelli FG, Grassi M, MaccarioViganoLanfranchi CML, Alferri Montrasio U, di Girolamo L (2018) Intracontidine adipose-derived stromal vascular fraction (SVF) injection provides a safe, efficacious treatment for Achilles tendinopathy: results of a randomized controlled clinical trial at a 6-month follow-up. Knee Surg Sports Traumatol Arthrosc 26:2000–2010
62. Van Genechten W, Vuylsteke K, Martinez PR, Swinnen I, Sas K, Verdonk P (2021) Autologous Micro-Fragmented Adipose Tissue (MFAT) to Treat Symptomatic Knee Osteoarthritis: Early Outcomes of a Consecutive Case Series. J Clin Med 10:2231
63. Vassos M, Cona La, Capasso L, Torio G, Schiavone Pannini A (2022) Intraarticular injection of microfragmented adipose tissue plus arthroscopy in isolated primary patellofemoral osteoarthritis is clinically effective and not affected by age, BMI, or stage of osteoarthritis. J Orthop Traumatol 23:7
64. Veronesi S, Dati Fr E, Coi G, Busato A, Mannucci S, Sbarbati A (2020) Comparative technical analysis of liposaprate mechanical processing devices. J Tissue Eng Regen Med 14(9):1213–1226
65. Vezzani B, Shaw J, Lesme H, Yong L, Khan N, Tremolada C, Pfeaut B (2018) Higher Pericyte Content and Secretory Activity of Microfragmented Human Adipose Tissue Compared to Enzymatically Derived Stromal Vascular Fraction. Stem Cells Transl Med 7:876–886
76. Vinet-Jones H, Darr F, K, (2020) Clinical use of autologous micro-frag-
    mented fat progressively restores pain and function in shoulder osteoar-
    thritis. Regen Med 15:2153–2161
77. Winnier GE, Valenzuela N, Peters-Hall J, Kellner J, Alt C, Alt EU (2019) Isola-
    tion of adipose tissue derived regenerative cells from human subcutane-
    ous tissue with or without the use of an enzymatic reagent. Shi X-M (ed)
    PLOS ONE 14:e0221457
78. Xue EY, Narvaez L, Chu CK, Hanson SE (2020) Fat Processing Techniques
    Semin Plast Surg 34(1):11–16
79. Züük PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, Benhaim P, Lorenz
    HP, Hedrick MH (2001) Multilineage cells from human adipose tissue:
    implications for cell-based therapies. Tissue Eng 7:211–228
80. CEBM Levels of Evidence Working Group. The Oxford Levels of Evidence
    2 [Internet]. Oxford Centre for Evidence-Based Medicine; [cited 2021 Nov
    15]. Available from: https://www.cebm.ox.ac.uk/resources/levels-of-evidence/cebm-levels-of-evidence.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.